Key clinical point: Midostaurin maintenance therapy after allogeneic stem cell transplant may improve relapse free survival in acute myeloid leukemia with FLT3 expression.
Major finding: Midostaurin maintenance improved relapse-free survival (hazard ratio, 0.46).
Study details: The phase 2 RADIUS trial of 60 patients with acute myeloid leukemia.
Disclosures: Dr. Maziarz reported financial relationships with Incyte, Novartis, Celgene/Juno, Kite/Gilead, Juno Therapeutics, Kite Therapeutics, and Athersys.
Transplantation and Cellular Therapy Meetings 2019
Must Reads in AML
IDH-mutated AML: First-line IDH inhibitors, chemo may up remission, Stein EM et al. ASH 2018, Abstract 560
Rapid genomic results possible, Beat AML trial suggests, Burd A et al. ASH 2018, Abstract 559
Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774